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Summary This case report describes a 54-year-old man presenting with loss of conscious-
ness due to acquired long QT syndrome shortly after ﬂecainide therapy. The patient had no
common risk factors for acquired long QT syndrome. Prior to onset of ventricular tachycardia,
bradyarrhythmia and short-long-short sequence were observed with a prolonged QT interval
of 710ms. However, the morphology of induced tachycardia was uniform rather than torsades
de pointes. We presumed that the properties of ﬂecainide, such as slowing conduction, con-
tribute partly in a use-dependent manner to development of uniform tachycardia. In addition,
we believe that prolongation of QT by ﬂecainide is exceedingly rare; however, it may be one
of the mechanisms of ﬂecainide-induced proarrhythmia.
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Introduction
Flecainide is a potent sodium-channel blocker, with slow
onset and offset kinetics [1]. It is known as a safe antiar-
rhythmic agent in patients with normal hearts and is used
widely in the treatment of atrial ﬁbrillation (AF). How-
ever, proarrhythmia by ﬂecainide may be fatal and may well
have been described in patients with structural heart dis-
ease. Acquired long QT syndrome (LQTs) is not included as
one of these proarrhythmic episodes and is very uncom-
mon because effects of ﬂecainide on repolarization are
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inimal [2]. Acquired LQTs is usually accompanied by tor-
ades de pointes and is induced by concomitant risk factors.
hese proarrhythmic episodes can result in sudden death
pon degeneration to ventricular ﬁbrillation. However, the
resent case report showed prolongation of QT interval by
ecainide without any usual risk factors. In addition, it even-
ually presented with uniform ventricular tachycardia (VT)
ather than torsades de pointes. We believe that the present
ase is a very rare one, demonstrating a direct relationship
etween ﬂecainide and acquired LQTs.ase report
54-year-old man who had a history of hypertension was
eferred for palpitation and chest discomfort lasting 5 days.
Published by Elsevier Ltd. All rights reserved.
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Figure 1 Electrocardiogram demonstrating atrial ﬁbrillation after rate control (rate = 88 bpm, QRS duration = 95ms, and QTc interval = 438ms).
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Figure 2 (A) Uniform, wide QRS tachycardia (cycle length = 440ms) with a right bundle branch block pattern and left axis deviation.
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cThis sine wave-like electrical activity may result from a slow b
(QT interval = 710ms and QTc interval = 680ms) and a short-long
He had received treatment with aspirin 200mg and perindo-
pril 4mg a day at a primary clinic. He had no prior history
of syncope or familial history of syncope, cardiac arrest, or
sudden cardiac death. Findings from physical examination
were unremarkable and an initial 12-lead electrocardiogram
(ECG) showed AF with rapid ventricular response. A chest
X-ray and chemistry data, including serum electrolytes, car-
diac enzyme, brain natriuretic peptide, and thyroid function
test were normal. Propranolol 120mg a day was prescribed
for 3 days and a follow up ECG demonstrated AF of 88 beats
per minute (bpm) (Fig. 1). Both QRS width and corrected QT
(QTc) interval were normal, at 95ms and 438ms, respec-
tively. Scintigraphic myocardial perfusion imaging showed
a normal stress study. On transthoracic echocardiography,
l
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sg—unbinding kinetic of ﬂecainide. (B) A prolonged QT interval
rt sequence followed by nonsustained ventricular tachycardia.
oth ventricles were found to be of normal size and thick-
ess, and the left ventricular ejection fraction was 52%
ithout regional wall motion abnormality. The patient was
rescribed ﬂecainide of 200mg and atenolol 25mg a day.
Five days later, he was admitted to the emergency
epartment due to repetitive loss of consciousness. The
nitial ECG revealed uniform, sine wave-like tachyarrhyth-
ia (cycle length = 440ms) with a right bundle branch block
attern and a left axis deviation (Fig. 2A). After electrical
ardioversion of 200J, a slow escape rhythm with ventricu-
ar premature beats was observed on ECGmonitoring. During
radycardia, a negative T wave was observed on the surface
CG and QTc interval reached 680ms. Multiple episodes of
ustained or nonsustained tachyarrhythmia with the same
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Figure 3 (A) Follow-up electrocardiogram during normal sinus rhythm. The corrected QT interval was prolonged (rate = 71 bpm, QRS duration = 102ms, and QTc interval = 556ms).
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RAcquired long QT syndrome and ventricular tachycardia in a
form occurred in succession by ventricular premature beats
with a short-long-short sequence (Fig. 2B). Chemistry data,
including cardiac enzymes and serum sodium, potassium,
magnesium, and calcium were still normal. After continuous
isoproterenol infusion, bradycardia showed improvement
and tachyarrhythmia was suppressed. On follow-up ECG,
prolonged QTc interval (QTc = 556ms) and T wave inver-
sion were still noted during normal sinus rhythm (rate = 71
bpm) (Fig. 3). Coronary angiography was unremarkable and
echocardiography showed a slightly decreased left ventric-
ular ejection fraction of 45% without other interval changes
from the initial study. Flecainide was discontinued; one
week later, AF was still noted but QTc interval was nor-
malized. He was discharged with amiodarone 100mg and
diltiazem 180mg a day after pacemaker implantation for
prevention of sinus dysfunction.
Discussion
Flecainide is known as a safe antiarrhythmic agent in
patients with normal hearts and is used widely in treat-
ment of AF. However, the proarrhythmic event by ﬂecainide
may be fatal and includes a paradoxical increase in ven-
tricular rate in atrial tachyarrhythmia, reduced excitability
of myocardium, and increased mortality in patients with
prior myocardial ischemia [1]. Aberrant conduction on
supraventricular tachycardia (SVT) with 1:1 conduction
is a well-known proarrhythmia in ﬂecainide use and it
should be differentiated from VT. In our case, diagno-
sis of VT from the initial ECG was not easy to conﬁrm.
We determined that the mode of tachycardia initiation
on following episodes favored VT rather than SVT with
aberrancy.
However, prolongation of QT interval without QRS widen-
ing by ﬂecainide is an uncommon proarrhythmic episode
[2]. Prolongation of QT interval is usually related to elec-
trolyte abnormalities, bradycardia, and exposure to certain
drugs, particularly class Ia and III antiarrhythmics [1]. In
the present case, QT interval was prolonged without these
risk factors and actually resulted in VT. Accompaniment of
sinus node dysfunction and bradyarrhythmia was initially
observed; however, QT prolongation was still observed after
recovery of normal sinus rhythm. We did not analyze genetic
mutation of ion channels. This limitation allows us to spec-
ulate about subclinical LQTs. However, the possibility of
congenital LQTs in the present case seems to be low, because
oral ﬂecainide has been known to usually shorten QT interval
rather than to prolong it in LQT3 patients with the genetic
defect of SCN5A, and proarrhythmic sensitivity would be
explained by a phenotype combining LQT3 and Brugada syn-
drome [3]. Also, in a case of KCNQ1 gene mutation, male
patients with LQT1 who are older than 25 years of age
have been known to be exceptional, because very seldom
does a ﬁrst event occur any later in this population [4].
Another assumption is about genetic polymorphism of drug
metabolism. It may help to explain the cause of adverse
events under the usual dosage of ﬂecainide, although we
did not measure the serum level of ﬂecainide. In the rare
patients with lack of active CYP2D6, ﬂecainide can accu-
mulate to toxic plasma concentrations [5]. Review of prior
literature found only a few case reports demonstrating aent on ﬂecainide therapy e141
irect relationship between ﬂecainide therapy and acquired
QTs and torsades de pointes [2,6].
Acquired LQTs is usually bradycardia-dependent and
hort-long-short sequences are frequently observed at
rrhythmia onset [7,8]. Typically triggered activity due to
arly after depolarizations (EAD) is initiated by a short-long-
hort sequence of complexes [7]. As in the present case,
he current role of triggered activity by EAD has been more
s an initiator of torsades de pointes in acquired LQTs [9].
ll of the prior reports showed ﬂecainide-induced torsades
e pointes under the same conditions [2,6]. However, our
ase showed uniform, sine-wave like VT at onset and during
aintenance of tachycardia, even though these electrical
ctivities were observed prior to onset of tachycardia. There
ay be some explanations. Some investigators have demon-
trated that EAD could give rise to a uniform tachycardia as
ell, and that there may be no obligatory link between EADs
nd torsades de pointes [7,8]. In addition, we assumed that
he electrophysiological property of ﬂecainide may give rise
o uniform VT. Flecainide blocks the fast sodium channel in a
se-dependent manner and primarily slows down conduction
y depression of the maximum rate of rise of depolarization
f the action potential with minimal effect on refractori-
ess [10]. Incessant uniform VT can develop with markedly
idened QRS complexes and a sine-wave morphology by
ntiarrhythmic agents that slow ventricular conduction, par-
icularly by class IA or IC [9,10]. We would like to explain
he main culprit perpetuating this arrhythmia as ventricu-
ar macroreentry associated with functional block that can
e a result of the slowing of conduction in a use-dependent
anner by ﬂecainide.
In the present case, we reported on an unusual proar-
hythmic episode in a patient who had undergone ﬂecainide
herapy. Without any risk factors, our case demonstrated
hat ﬂecainide treatment can result in development of
cquired LQTs with uniform VT in a patient with no history
f VT. We believe that prolongation of QT by ﬂecainide is
xceedingly rare; however, it may be one of the mechanisms
f ﬂecainide-induced proarrhythmia.
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